Table IV.
Model 1 | Model 2 | |||||
---|---|---|---|---|---|---|
Risk factor | Wheeze (%) (n = 58) | Control (%) (n = 35) | Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value |
Sensitization to inhalant allergens (IgE ≥0.7 kUA/L)∗ | 42/58 (72.4) | 15/35 (42.8) | 2.7 (1.06 to 7.1) | .03 | — | — |
Sensitization to inhalant allergens (IgE ≥3.5 kUA/L)∗ | 36/58 (62) | 7/35 (20) | — | — | 5.7 (1.9 to 16.7) | .001 |
Viral infection† | 19/58 (32.7) | 9/35 (25.7) | 1.3 (0.4 to 3.6) | .5 | 1.1 (0.4 to 2.9) | .8 |
Family history of allergy‡ | 38/58 (65.5) | 22/35 (62.8) | 1.1 (0.4 to 3.0) | .7 | 1.0 (0.4 to 2.9) | .8 |
Specific IgE to Ascaris lumbricoides(IgE ≥0.7 kUA/L)§ | 19/56 (33.9) | 5/35 (14.2) | 2.1 (0.6 to 7.2) | .2 | 1.5 (0.4 to 5.4) | .5 |
Sex, male | 34/58 (58.6) | 22/35 (62.8) | 1.1 (0.4 to 3.0) | .7 | 1.1 (0.4 to 2.9) | .8 |
Sensitization defined as IgE antibody levels ≥0.7 kUA/L (model 1) or IgE antibody levels ≥3.5 kUA/L (model 2) to at least 1 inhalant allergen (mites, cockroach, cat, dog).
Detection of rhinovirus RNA, coronavirus RNA, adenovirus B, and/or RSV antigen in nasal washings.
History of asthma, rhinitis, and/or atopic dermatitis in parent(s) and/or siblings.
Positive specific IgE defined as IgE antibody levels ≥0.7 kUA/L to Ascaris lumbricoides.